Search the Newsreel

Medical-device sales leader with more than 30 years returns to InspireMD

InspireMD (Nasdaq: NSPR) has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, with over 30 years of medical device sales leadership, previously supported the U.S. launch of CGuard Prime and returns to help prepare for its potential U.S. commercial …

LifeMD Inc (LFMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of LifeMD Inc (LFMD), noting its current valuation score of 9.86 and its rank within the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio, comparing it to recent highs and lows. The article also …

InspireMD appoints Kathleen Kennedy as SVP of global sales By Investing.com

InspireMD, Inc. has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, who previously served as Sales Director for InspireMD, brings over 30 years of medical device sales leadership experience and will report to CEO Marvin Slosman. Her appointment aligns …

InspireMD Inc.: InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

InspireMD, Inc. has announced the appointment of Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, with over 30 years of medical device sales leadership experience, including in carotid intervention, will report to CEO Marvin Slosman. Her role will be crucial …

Earnings call transcript: Emyria posts 210% revenue growth in Q4 2026

InspireMD Inc (NSPR) Institutional Confidence

InspireMD Inc (NSPR) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 49.38%, marking a 9.65% decrease quarter-over-quarter. James Simons is the largest institutional shareholder with 32.63K shares, …

LifeMD (LFMD) Projected to Announce Quarterly Earnings on Wednesday

Emyria Delivers $4.3 Million Full-Year Revenue as Victorian Clinic Opens and Depression Treatment Data Improves

LifeMD Inc (LFMD) Institutional Confidence

LifeMD Inc (LFMD) currently has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 42.85%, showing a slight quarter-over-quarter decrease of 0.30%. The largest institutional shareholder is Bill Nygren …

NSPR|InspireMD Inc|Price:0.694|Chg%:+0.010

This article provides a detailed company profile for InspireMD Inc (NSPR), a medical device company specializing in MicroNet stent platform technology for vascular and coronary disease treatment. It covers the company's business scope, financial data, market performance, executive team, and institutional shareholding. The key …

InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of InspireMD Inc (NSPR), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types and institutional holdings over several quarters, along with recent changes in individual institutional holdings.

InspireMD Inc (NSPR) Cash Flow

This article provides a detailed cash flow statement for InspireMD Inc (NSPR), presenting quarterly and annual data for operating, investing, and financing activities over several years. It includes key figures such as operating cash flow, net income from continuing operations, capital expenditures, and free …

LifeMD Inc (LFMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of LifeMD Inc (LFMD), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholders by type and provides a historical overview of institutional shareholding, including the number of institutions, shares held, …

LifeMD Inc (LFMD) Income Statement

This article provides the quarterly and annual income statements for LifeMD Inc (LFMD), offering detailed financial data on revenues, expenses, and net income over a prolonged period. It includes year-over-year percentage changes for various financial metrics, helping investors assess the company's performance and operational …

InspireMD Inc. Revenue Breakdown – NASDAQ:NSPR

InspireMD Inc. (NASDAQ: NSPR) generated $8.98 million USD in revenue last year, primarily from its CGuard Carotid Embolic Prevention System segment, which also brought in $8.98 million USD. The company's "Other" segment contributed $4.06 million USD to its revenue. This indicates a significant portion …

LFMD|LifeMD Inc|Price:3.710|Chg%:-0.160

LifeMD Inc. (LFMD) is a virtual healthcare and pharmacy service provider with strong fundamentals and high growth potential, though its stock performance has been weak recently. The company's valuation is considered fairly valued within its industry, and it has a high institutional ownership. Analysts …

LifeMD schedules Aug. 5 update after U.S. markets close

LifeMD (Nasdaq: LFMD) is scheduled to report its second-quarter and first-half 2026 financial results on August 5, 2026, after the U.S. market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss these results. Historical data shows that prior …

LifeMD to Report Second Quarter 2026 Financial Results on August 5

LifeMD, Inc. (Nasdaq: LFMD) announced it will release its financial results for the second quarter and six months ended June 30, 2026, after the U.S. financial markets close on August 5, 2026. The company will also host a conference call on the same day …

InspireMD Receives Nasdaq Minimum Bid Price Warning

InspireMD Inc. announced it has received a warning from Nasdaq regarding non-compliance with the minimum bid price rule. The company now has a 180-day grace period, until January 20, 2027, to regain compliance by having its common stock close at $1.00 or more for …

Lifemd, Inc. (LFMD) Q4 2023 Earnings Report - Results, Call & Slides

LifeMD (LFMD) announced its Q4 2023 earnings, reporting an actual EPS of -$0.12, beating the consensus of -$0.14 by $0.02. The company also surpassed revenue expectations, with actual revenue of $44.86M against an expected $41.30M, representing a 59.53% year-over-year growth. The earnings call was …

InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for InspireMD Inc (NSPR), noting its current valuation score is 7.68, ranking 136 out of 200 in its industry. It highlights the company's P/E ratio of -0.99, which is significantly below its recent high and above its recent …

InspireMD Disclosed Failure to Satisfy a Continued Listing Rule or Standard

InspireMD (NSPR) received a notice from Nasdaq on July 17, 2026, indicating its failure to meet the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has 180 days, until January 13, 2027, to regain compliance while its stock continues …

InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk

InspireMD, Inc. (NSPR) received a notice from Nasdaq on July 17, 2026, indicating non-compliance with the minimum $1.00 bid price requirement. The company has 180 calendar days, until January 13, 2027, to regain compliance by achieving a closing bid price of at least $1.00 …

InspireMD gets Nasdaq notice for failing $1 minimum bid price rule

InspireMD (NSPR) received a Nasdaq notice on July 17, 2026, for failing to maintain the minimum $1 bid price, based on closing prices from June 3 to July 16. The company has until January 13, 2027, to regain compliance by achieving a $1 or …

Emyria (ASX:EMD) Posts A$1.55M Revenue—Is the Healthcare Innovator Moving Closer to Commercial Scale?

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key Support - Market Leader Picks

InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares Slide - Return On Capital

Emyria (ASX:EMD) Positions for Empax Growth with Victorian Patient Rollout

Earnings call transcript: LifeMD Q1 2026 beats EPS and revenue forecasts

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause

InspireMD Reports 53% Year-Over-Year Unit Sales Growth Amid Anticipated FDA Approvals and Voluntary Recall of CGuard Prime 135 cm Delivery System | NSPR Stock News

After the bell May 6: LifeMD sets Q1 results call for 4:30 p.m. ET

How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations